Medicare Part D coverage · diflunisal · RxCUI 2691103
diflunisal 375 MG Oral Tablet [Dolobid]
Per the CMS 2026 Part D formulary file, diflunisal 375 MG Oral Tablet [Dolobid] is covered by 115 Medicare Part D plans (2.3% of enrollable products), averaging Tier 5, with prior authorization required on 0% of covering formularies.
- 2.3%
- Plan coverage
- 115
- Plans covering
- T5
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for diflunisal 375 MG Oral Tablet [Dolobid]
Per the CMS 2026 Part D formulary file, diflunisal 375 MG Oral Tablet [Dolobid] (RxNorm concept RXCUI 2691103, generic name diflunisal) appears on 2 distinct formulary files spanning 115 Medicare Part D plan offerings - 2.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.
Real-world access to diflunisal 375 MG Oral Tablet [Dolobid] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 3,325 Part D beneficiaries filled diflunisal 375 MG Oral Tablet [Dolobid] in 2023, with total plan-and-beneficiary spending of $855,515 and an average per-beneficiary annual cost of $257.30. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry diflunisal 375 MG Oral Tablet [Dolobid] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 115
- Coverage rate
- 2.3%
- Tier range
- Tier 5, Specialty
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 3,325
- Total spending
- $855,515
- Avg per beneficiary
- $257.30
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering diflunisal 375 MG Oral Tablet [Dolobid]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is diflunisal 375 MG Oral Tablet [Dolobid] covered by Medicare Part D?
Yes, diflunisal 375 MG Oral Tablet [Dolobid] is covered by 115 Medicare Part D plans (2.3% of all Part D formularies).
What tier is diflunisal 375 MG Oral Tablet [Dolobid] on Medicare Part D plans?
diflunisal 375 MG Oral Tablet [Dolobid] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.
Does diflunisal 375 MG Oral Tablet [Dolobid] require prior authorization?
0% of Part D formularies require prior authorization for diflunisal 375 MG Oral Tablet [Dolobid]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on diflunisal 375 MG Oral Tablet [Dolobid]?
In 2023, total Medicare Part D spending on diflunisal 375 MG Oral Tablet [Dolobid] was $855,515, covering 3,325 beneficiaries. The average spend per beneficiary was $257.30.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 0.8 ML adalimumab-adaz 100 MG/ML Auto-Injector T5
- metronidazole 10 MG/ML Topical Cream [Noritate] T5
- 1 ML ustekinumab-ttwe 90 MG/ML Prefilled Syringe T5
- formoterol fumarate 0.01 MG/ML Inhalation Solution [Perforomist] T5
- deferiprone 1000 MG Oral Tablet [Ferriprox] T5
- ruxolitinib 15 MG/ML Topical Cream [Opzelura] T5